Owkin Teams Up with AWS to Advance GenAI for Precision Medicine

Owkin, a TechBio that combines human and artificial intelligence to find the right treatment for every patient, announced they are working with Amazon Web Services to transform drug discovery, de-risk and accelerate clinical trials, and develop AI diagnostics. Owkin will leverage AWS’s proven global infrastructure and secure, extensive, and reliable cloud platform to enhance data operations, optimize for operational excellence, and drive forward research in precision medicine.

"Owkin was founded with the belief that the future of precision medicine is in technologies that can unlock insights from the vast amount of patient data in hospitals and research centers in a privacy-preserving and secure way. Beyond our cutting-edge technologies, our strongest asset is in the power of collective intelligence through collaboration,” said Thomas Clozel, cofounder and CEO of Owkin.

By integrating research and development in biotech with AWS's secure and scalable cloud infrastructure and services, Owkin can meet its petabyte-level storage needs, develop generative AI applications, and build and adapt foundation models. Owkin will use Amazon SageMaker to build, train, and deploy machine learning models, optimize the processing of high-quality data at scale, and advance the deployment of its portfolio of AI solutions through research partners, pathology labs, and biopharma, ultimately better servicing patient health outcomes.

Owkin and experts from AWS’s Healthcare and Life Sciences team, who bring hands-on experience from pharma, medical device, biotech, and government health and regulatory organizations, will work to harness technology to address critical challenges in precision medicine and find the right treatment for every patient. Utilizing their respective expertise, Owkin and AWS aim to facilitate ground-breaking discoveries and drive the development of transformative solutions for global healthcare challenges.